Drug resistance is a major obstacle for the success of conventional anticancer therapy, and the development of drug resistance is at least partly attributed to tumor propagating cells (TPCs). Up to one-third of diffuse large B cell lymphoma (DLBCL) patients eventually develop resistance to R-CHOP regimen. We found that the TPC proportion was remarkably increased in resistant germinal center B cell-like (GCB) and activated B cell-like (ABC) DLBCL subtypes. Elevated SOX2 was the determinant for resistance development, and SOX2 was phosphorylated by activated PI3K/AKT1 signaling, thus preventing ubiquitin-mediated SOX2 degradation. Furthermore, multiple factors, including BCR, integrins, chemokines and FGFR1/2 signaling, regulated PI3K/AKT1 activation. CDK6 in the GCB subtype and FGFR1/2 in the ABC subtype were SOX2 targets in the PI3K/AKT1 pathway. Chemical inhibition of PI3K/AKT1 in both subtypes, CDK6 in the GCB subtype, and FGFR1/2 in the ABC subtype significantly enhanced the susceptibility of resistant cells to CHO treatment. More importantly, PI3K and FGFR1/2 inhibitors but not a CDK6 inhibitor effectively suppressed the tumor growth of R-CHO-resistant DLBCL cells, most likely by converting TPCs to chemo-sensitive differentiated cells. Therefore, this pro-differentiation therapy against TPCs warrants further study in clinical trials for the treatment of resistant DLBCL.
Introduction
The success of conventional anticancer therapy is frequently hindered by drug resistance. Such acquired resistance results at least partly from intratumoral heterogeneity that is accounted for the predominant differentiated cancer cells and the tiny subpopulation of tumor propagating cells (TPCs). Although most differentiated cells are eliminated by conventional therapy, TPCs survive, which may drive drug resistance development (1, 2) . TPCs are characterized by distinct surface proteins, self-renewal, differentiation, quiescence, and a high association with drug resistance, recurrence and metastasis (2) (3) (4) (5) .
Therefore, a combination of conventional therapy and TPC-specific therapy is strongly indicated and being pursued (6, 7) . SOX2, a pluripotency-associated transcription factor, is critical for embryonic (8) and induced pluripotent stem cells (9) ; however, its expression is highly detrimental in at least 25 different cancers (10) . In contrast with numerous studies focusing on SOX2 regulation by non-coding RNAs, there have been limited reports concerning transcriptional regulation and post-translational modifications. PI3K/AKT1 signaling is a master regulator not only in tumorigenesis, tumor progression, and drug resistance (11) but also in TPC biology (12) . Interestingly, PI3K/AKT1 may suppress SOX2 ubiquitination via a methylation (K119)-phosphorylation (T118) switch in SOX2, thus stabilizing SOX2 (13) .
Non-Hodgkin's lymphoma (NHL) ranks in the top 10 causes of cancer mortality, and diffuse large B cell lymphoma (DLBCL) is the most common subtype (14) . DLBCL can be subdivided into three distinct cell-of-origin subtypes: germinal center B cell-like (GCB), activated B cell-like (ABC), and 10-20% primary mediastinal B cell lymphoma (PMBL) subtypes (15) . Although more than half of DLBCL patients can be cured, mainly by R-CHOP (rituximab/R, cyclophosphamide/C, doxorubicin/H, vincristine/O, and prednisone/P) regimens (16) , up to one-third of patients will eventually develop relapsed/refractory disease (17) . Our growing understanding of the molecular basis of resistance has led to the development of a large number of novel interventions, however, they are only being tested in phase I or II trials, and no single agent or regimen provides long-term disease control (18, 19) . Thus, novel therapeutic approaches for relapsed/refractory DLBCL are urgently needed.
Here we found a remarkably elevated proportion of TPCs in resistant DLBCL cells, whose stemness was regulated by the activated PI3K/AKT1/SOX2 axis. Further, PI3K/AKT inhibitor converted TPCs to differentiated tumor cells by reducing SOX2 level, thus preventing the growth of implanted resistant cells when combined with the R-CHOP regimen.
Methods

DLBCL tissue samples, cell lines and reagents
We examined the medical history of all DLBCL patients from 2008 to 2015 at Fudan University Shanghai Cancer Center and found a total of 12 patients who simultaneously had both paraffin-embedded tissue samples from the initial visit and from relapse. DLBCL cases were subgrouped into GCB (6 cases) or ABC (6 cases) molecular subtypes based on the Hans immunohistochemistry algorithm. Additional information is provided in the supplemental material.
Generation and characterization of RCHO-resistant DLBCL cells
We generated RCHO-resistant LY8 (OCI-Ly8) and NU-DUL-1 cells as previously described and details are described in the supplemental material (20, 21) .
Aldefluor Assay
ALDH1 is a selectable marker for multiple kinds of normal and cancer stem cells, including hematopoietic stem cells (22, 23) . Thus, we evaluated tumor propagating cell numbers in hematopoietic malignancies using an ALDEFLUOR™ kit (StemCell Technologies, Vancouver, BC, CA) to detect ALDH1 + cells. Details are described in the supplemental material.
Sphere Formation Assay
We conducted sphere formation assays as previously described and details are reported in the supplemental material (24) .
CytoTox-Glo™ Cytotoxicity Assay
We used a CytoTox-Glo™ cytotoxicity assay kit (Promega, Madison, WI) to evaluate cytotoxicity according to the technical bulletin. Details are described in the supplemental material.
Immunohistochemistry
Tumor tissues derived from patients or animal models were fixed with 4% formalin, embedded in paraffin and sectioned. Immunohistochemistry (IHC) staining was performed on 4 μm paraffin sections and details are provided in the supplemental material.
Immunoblotting Assay
We performed immunoblotting assays according to the standard protocol, and the related antibodies are shown in Table S1 .
Quantitative Real-time PCR (qRT-PCR)
We performed qRT-PCR as previously described and details are reported in the supplemental material (24) . The primers for qRT-PCR are listed in Table  S2 .
FACS Analysis
Flow cytometric analysis was performed on a Cytomics FC500 MPL instrument (Beckman Coulter, Brea, CA) and analyzed with FlowJo software (Ashland, OR). We performed cell sorting with a MoFlo XDP instrument (Beckman Coulter, Brea, CA). Details are described in the supplemental material.
EdU Cell Proliferation Assay
The EdU cell proliferation assays were performed using the Cell-Light EdU Apollo643 In Vitro Flow Cytometry Kit (Guangzhou RiboBio Co., Ltd., Guangzhou, China). Details are described in the supplemental material.
Plasmid Construction and Lentiviral Transduction
The plasmid construction and lentiviral transduction was performed as previously described and details are depicted in the supplemental material (24) .
Information about shRNA oligonucleotide sequences is shown in Table S2 .
Xenograft Model
All the animal experiments were conducted in strict accordance with experimental protocols approved by the Animal Ethics Committee at Shanghai Medical School, Fudan University. Eight-week-old female SCID mice were purchased from Slac Laboratory Animal Center (Shanghai, China) for injection with RCHO-resistant DLBCL cells. The methods of drug delivery based on the clinical usage for one cycle are indicated in Table S3 . Tumor growth was monitored by bioluminescence at 50, 70 and 90 days after implantation using an In Vivo MS FX PRO system (Bruker, Billerica, MA). The surviving mice were euthanized and dissected at 120 days after xenografting, and no intraperitoneal tumors were found. Tumor tissues were immediately collected from the moribund mice after euthanatized by CO 2 . Additional information including serial-transplantation for detecting tumor-initiating capacity of RCHO-resistant cells is provided in the supplemental material.
RNA Sequencing and Bioinformatic Analysis
Total RNA was extracted from LY8-ORI, LY8-R, LY8-CHO, LY8-RCHO, NU-DUL-1, NU-DUL-1-R, NU-DUL-1-CHO, and NU-DUL-1-RCHO cells with TRIzol reagent (Invitrogen, Grand Island, NY). The total RNA from each group from 3 different passages was pooled separately. RNA sequencing (RNA-seq) and bioinformatics analysis were conducted by Shanghai Novelbio Ltd. (25) .
Details are decribed in the supplemental material.
Results
Resistance of stem-like resistant DLBCL cells was regulated by SOX2.
Antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) are the major mechanisms underlying R therapeutic effect (26, 27) . Resistance to ADCC may derive from intrinsic features of immune cells of individual patient, such as FcGRIIIA polymorphism and CD47 expression (28, 29) ; while resistance to CDC is mediated by a low expression level of CD20 and/or high expression levels of membrane-bound complement regulatory proteins (mCRPs), including CD46, CD55 and especially CD59 (27, 30) . Although few studies have experimentally demonstrated the presence of TPCs in NHL, they are still proposed to exist (31, 32) . Thus, we employed ALDH1 (33) and side population (34) in TPCs of various cancer types and CD34 and CD133 in TPCs of leukemia (35, 36) to ascertain the stemness of resistant DLBCL cells. The results showed a significantly elevated proportion of ALDH1 + , side population, CD34 + and CD133 + cells in the resistant cells ( Fig. 1C -F, and
Fig. S1C-F), in which the increase of CD34 and CD133 levels were further verified by immunoblotting ( Fig. 1G ). These TPC markers may group different subpopulation with partially overlapping, for example, a small fraction of cells showed CD133 + among ALDH1 + cells ( Fig. S2 ) as described previously (37) .
In addition, we also observed that the expression of PAX5, a B cell commitment factor (38) , reduced in parallel with the resistance degree ( Fig.   1G ). More importantly, using serial-transplantation assay we revealed that both RCHO-resistant LY8 and NU-DUL-1 cells displayed higher tumor-initiating capacity than original cells (Table 1) . Together, these results strongly demonstrated that TPCs were highly enriched in the resistant DLBCL cells.
To examine the molecular regulation of stemness in the resistant cells, we detected the expression of core stemness-associated transcription factors, SOX2, OCT4, NANOG, KLF4 and c-Myc. As shown in Fig. 1H , only SOX2 level gradually increased along with the tendency toward resistance. Moreover, in clinical specimens from DLBCL patients, we observed that SOX2 staining in We next investigated the mechanism responsible for SOX2 upregulation in resistant DLBCL cells. Unexpectedly, the SOX2 mRNA level significantly declined in resistant cells, particularly in resistant LY8 cells ( Fig. 2A ), indicating that transcriptional regulation did not contribute to SOX2 overexpression.
Based on the RNA-seq data for the original and resistant cells, the interaction score from the KEGG pathway analysis showed that the PI3K/AKT signaling pathway and steroid biosynthesis were the most enriched pathways ( Fig. 2B and Supplementary Data 1). Furthermore, gene set enrichment analysis (GSEA) demonstrated that the gene signatures for the PI3K/AKT signaling pathway were significantly activated in both RCHO-resistant cell lines ( Fig. 2C and Supplementary Data 2). Experimentally, the result of flow cytometry also revealed that SOX2 + subpopulation exhibited higher AKT1 (S473) phosphorylation level than SOX2subpopulation in both RCHO-resistant LY8
and NU-DUL-1 cells ( Fig. S5 ). Meanwhile, AKT1 (S473) phosphorylation was confirmed to remarkably increase in accordance with the resistance degree accompanied by the subsequently increased phosphorylation of its substrate PRAS40, thus enhancing SOX2 (T118) phosphorylation and subsequently suppressing SOX2 (K119) methylation in both cell lines. In addition, expression of the PI3K subunit p110α/δ and p85 in resistant LY8 cells and p110γ in resistant NU-DUL-1 cells were also elevated ( Fig. 2D ). Consistently, for both GCB and ABC subtypes, AKT1 (S473) phosphorylation was also significantly increased in the relapsed biopsy tissues versus the paired patient tissues from the initial visit ( Fig. 2E and Fig. S6 ). The switch of SOX2 phosphorylation-methylation, which is regulated by PI3K/AKT1, was confirmed to regulate SOX2 stabilization via the ubiquitin system (13) . Consistently, ubiquitinated-SOX2 was markedly reduced in resistant cells ( (Fig. 3G) . Further, the reduction of CD79A expression suppressed the BCR/Lyn/Syk/AKT1 signaling axis, thus inducing SOX2 instability (Fig. 3H ). These results demonstrate that BCR signaling positively regulates the level of SOX2 protein (Fig. 3B ). Moreover, we further investigated chemokine expression, which was suggested to activate the PI3K/AKT1 pathway (Fig. 3B) . The GSEA results also showed that the chemokine signaling pathway was significantly enriched in RCHO-resistant LY8 cells but not in NU-DUL-1 cells (Fig. 3I , and Supplementary Data 4); the top 10 related genes are shown in Fig. 3J . We verified that CCR7 was ranked number 1 and found dramatically elevated CCR7 mRNA levels in different resistant LY8 cells, especially RCHO-resistant cells (Fig. 3K ). The CCR7 protein levels were consistently elevated, especially in CHO-and RCHO-resistant LY8 cells (Fig. 3L, left) ; in addition, CCR7 expression was elevated in resistant NU-DUL-1 cells, although to a lesser extent (Fig. 3L, right) .
Reduction of CCR7 expression impaired Src/AKT1 signaling, thus resulting in SOX2 degradation in both RCHO-resistant cell lines (Fig. 3M) .
Next, we functionally tested the effect of inhibitors of the above signaling molecules on reversing resistance to chemotherapy (CHO) in resistant cells.
Treatment with the PI3K inhibitor duvelisib alone induced marginal, if any, cytotoxicity; however, additive treatment with duvelisib and CHO dramatically enhanced the cytotoxic effect of CHO in both RCHO-resistant cell lines in a dose-dependent manner (Fig. 3N) . Similarly, treatment with a FAK, Syk, or Src inhibitor alone induced negligible cytotoxicity; however, combination treatment with CHO significantly enhanced the cytotoxic effect of CHO, but to a much smaller degree than the duvelisib combination (Fig. S8) . The sensitizing effect of duvelisib resulted most likely from the fact that duvelisib in advance reduced the proportion of TPCs in RCHO-resistant cells determined by the sphere formation assay and ALDH1 + cell measurement (Fig. S9 ). In addition, copanlisib, the first approved PI3K inhibitor with potent p110α/δ activities (42) , displayed the similar effect with duvelisib that copanlisib also significantly sensitized the RCHO-resistant cells to CHO treatment due to AKT1 inhibition and resultant SOX2 degradation (Fig. S10 ). To summarize, the elevated PI3K/AKT1 signaling in resistant LY8 and NU-DUL-1 cells was induced by multiple factors, including integrins, BCR and chemokine signaling, and inhibition of PI3K/AKT1 but not of either upstream pathways effectively suppressed resistant cell survival during chemotherapy, perhaps by reducing TPC proportion.
SOX2-regulated CD20 expression involved in the resistance development to R-induced CDC.
We further investigated the mechanisms for the development of resistance to R-induced CDC. In both LY8 and NU-DUL-1 R-and RCHO-resistant cells, CD20 membrane expression was dramatically reduced, while the expression of three mCRPs was slightly decreased (Fig. S11A ). Further, total CD20 level detected by immunoblotting showed the similar result ( Fig. S11B) , indicating that the significantly reduced membrane level of CD20 most likely resulted from transcription suppression (Fig. S11C) .
The critical role of SOX2 in resistance to rituximab-mediated CDC in DLBCL has been previously demonstrated (Fig. 1J) , and thus, we further examined the underlying mechanism. In both the original LY8 and NU-DUL-1 cells, ectopic SOX2 expression markedly reduced and SOX2 insufficiency dramatically increased CD20 expression ( Fig. S11D) . However, the expression of three mCRPs was not consistently associated with the resistance to rituximab-mediated CDC (Fig. S11D) . These results suggest that CD20 expression regulated by SOX2 is the determining factor in DLBCL resistance to rituximab-mediated CDC compared with mCRPs.
We further determined the effect of PI3K/AKT inhibitors on rituximab-mediated CDC. Both PI3K and AKT suppression considerably reduced CD20 expression, while the expression levels of the three mCRPs were not significantly altered in either RCHO-resistant cell lines (Fig. S11E) .
Similarly, the reduced CD20 expression most likely resulted from suppressed transcription ( Fig. S11F ). AKT1 inhibition together with CD20 and SOX2 expression was confirmed by immunoblotting ( Fig. S11G ). These results also suggested that PI3K/AKT1 might regulate CD20 expression independently of SOX2. Subsequently, PI3K/AKT inhibition was found to impair rituximab-mediated CDC in RCHO-resistant cells (Fig. S11H ). In addition, another PI3K inhibitor copanlisib also showed the similar effect with duvelisib that it conversely increased resistance to R treatment mostly by reducing CD20 level (Fig. S12 ). Therefore, in contrast with their effect on reversing resistance to chemotherapy, PI3K/AKT inhibitors might instead exacerbate resistance to rituximab-mediated CDC.
GCB and ABC cells employed different SOX2-targeted signaling molecules to develop resistance.
Given the effect of PI3K/AKT inhibition or SOX2 insufficiency on reversing resistance to R and/or CHO treatment, we analyzed up-regulated genes in the PI3K/AKT pathway ( Fig. 2C and was highly expressed in resistant LY8 cells ( Fig. 4B ) and relapsed GCB but not in ABC subtype DLBCL tissues ( Fig. 4C and Fig. S13 ). Consistently, FGFR1/2 were overexpressed in resistant NU-DUL-1 cells ( Fig. 4D ) and relapsed ABC but not in GCB subtype DLBCL tissues ( Fig. 4E and F, and Fig. S14 and S15).
Moreover, SOX2 + subpopulation expressed higher CDK6 or FGFR1/2 than SOX2subpopulation in RCHO-resistant LY8 or NU-DUL-1 cells, respectively ( Fig. S16) , further indicating the close association between SOX2 and CDK6 or FGFR1/2. PI3K inhibition with duvelisib suppressed AKT1 and PRAS40 phosphorylation and induced SOX2 degradation, thus reducing CDK6 expression in LY8 RCHO-resistant cells (Fig. 4G ) or FGFR1/2 expression in NU-DUL-1 RCHO-resistant cells (Fig. 4H) in a time dependent manner. We observed that SOX2 and OCT4 levels reduced starting from 2 or 24 (Fig. S4D) hours, respectively, after duvelisib treatment in both RCHO-resistant cells, indicating the different regulation of SOX2 and OCT4 in the resistant cells.
Duvelisib effect on LY8 RCHO-resistant cells was more transient than that in NU-DUL-1 RCHO-resistant cells (Fig. 4G and H) , which resulted probably from the diverse metabolic features in different cell types. Duvelisib also displayed dose-effect relationship with above molecules (Fig. 4I and J) . Similar to the effect of PI3K inhibition, CDK6 inhibition with abemaciclib in RCHO-resistant LY8 cells or FGFR1/2 inhibition with AZD454 in RCHO-resistant NU-DUL-1 cells considerably enhanced the cytotoxicity of CHO, while these inhibitors alone displayed a negligible cytotoxic effect on the resistant cells ( Fig. 4K and   L ). However, CDK6 inhibition in LY8-RCHO or FGFR1/2 inhibition in NU-DUL-1-RCHO-resistant cells failed to reverse resistance to R-mediated CDC ( Fig. 4M and N) . These results indicated that inhibition of SOX2 targets (CDK6 in LY8-RCHO-resistant cells and FGFR1/2 in NU-DUL-1-RCHO-resistant cells) could at least partly reverse resistance to chemotherapy but not to R-mediated CDC.
PI3K/AKT Inhibition promoted TPCs differentiation by reducing SOX2.
We next investigated the role of PI3K/AKT/SOX2 axis in stemness maintenance. The expression levels of CD34, CD133 were clearly reduced after PI3K inhibition in both RCHO-resistant cell lines (Fig 5A) , whereas CDK6 inhibition had no significant effect on the expression of the above molecules ( Fig 5A) . However, the expression levels of the above molecules also decreased after FGFR1/2 inhibition but to a smaller extent than those after PI3K inhibition ( Fig 5A) . In addition, PI3K inhibition significantly reduced the proportion of TPCs (marked as ALDH1 + cells) in both RCHO-resistant cell lines ( Fig. 5B and C) ; whereas CDK6 inhibition failed to change the proportion of TPCs in LY8 RCHO-resistant cells (Fig. 5B ). However, FGFR1/2 inhibition also significantly reduced the proportion of TPCs in NU-DUL-1 RCHO-resistant cells but to a much smaller degree than that with PI3K inhibition (Fig. 5C ), in agreement with a previous report showing that PI3K/AKT1 may be activated by FGFR signaling (45) . Notably, FGFR1/2 were up-regulated and participated in PI3K/AKT1 signaling activation ( Supplementary Data 3) ; thus, their inhibition reduced AKT1 phosphorylation and SOX2 stabilization (Fig. 5A) . These results revealed that PI3K/AKT1 inhibition directly by duvelisib or indirectly by AZD4547 promoted TPCs differentiation.
Differentiated tumor cells grow faster than TPCs. Indeed, SOX2 + subpopulation showed less EdU positive cells than SOX2subpopulation in RCHO-resistant LY8 and NU-DUL-1 cells (Fig. 5D ). Further, both RCHO-resistant cells grew more slowly than their related original cells in the in vivo serial-transplantation experiment with 5x10 6 cells injection ( Fig. 5E and F) , in which both RCHO-resistant and original cells induced 100% tumor incidence (Table 1) . PI3K/AKT inhibition effectively converted TPCs to differentiated cells, while CDK6 inhibition might directly suppress TPC growth through cell cycle targeting, and FGFR1/2 might have a dual effect on TPCs. All of these interventions eventually enhanced the TPC susceptibility to chemotherapy with varying efficacy.
Pro-differentiation therapy against TPCs by combining a PI3K inhibitor
with R-CHOP suppressed tumor growth of RCHO-resistant cells.
RCHO-resistant LY8
and NU-DUL-1 cells transduced with luciferase-expressing plasmid were separately implanted into immuno-deficient mice, and various therapeutic regimens were administered.
In mice bearing RCHO-resistant LY8 cells, R-CHOP treatment had no therapeutic effect on tumor growth compared with the saline control ( Fig. 6A and B), although R-CHOP significantly prolonged the survival rate (Fig. 6C) .
These results suggested that the in vitro resistance of LY8 cells to RCHO was recapitulated in mice to a high degree. Neither duvelisib nor abemaciclib alone suppressed tumor growth or prolonged the survival rate ( Fig. 6A-C) ; however, duvelisib accelerated tumor growth compared with saline, and although this difference was not statistically significant ( Fig. 6A and B) , it led to a significantly shortened survival rate (Fig. 6C) . In contrast, when combined with R-CHOP, duvelisib or abemaciclib dramatically suppressed tumor growth and prolonged survival compared with R-CHOP or inhibitor alone ( Fig. 6A-C) . More importantly, duvelisib combination therapy effectively suppressed tumorigenesis, and all the treated mice survived until the experimental end-point at day 120 compared with two mice receiving abemaciclib combination therapy that died on days 62 and 78 ( Fig. 6A-C) . Similar but not identical results were obtained in mice bearing RCHO-resistant NU-DUL-1 cells. R-CHOP significantly suppressed tumor growth and prolonged survival ( Fig. 6D-F) , likely due to the weaker stemness and reduced TPC proportions, resulting in weaker resistance than RCHO-resistant LY8 cells (Fig. 1 B-F ).
Duvelisib alone also had no therapeutic effect on tumor growth and survival, whereas AZD4547 alone significantly prolonged survival ( Fig. 6D-F) .
Importantly, when combined with R-CHOP, both duvelisib and AZD4547 effectively suppressed tumor growth and prolonged survival up to the experimental end-point of day 120 ( Fig. 6D-F) . These different tumor-suppressing effects of duvelisib, abemaciclib and AZD4547 further support their potentially distinct resistance-reversing mechanisms; i.e., duvelisib converted TPCs to differentiated cells, abemaciclib inhibited TPC growth, and AZD4547 exhibited dual effects on TPCs. SOX2 staining of the implanted tumor tissues with different treatments supported this finding.
Duvelisib or AZD4547, but not R-CHOP or abemaciclib, dramatically reduced SOX2 expression ( Fig. 6G and H ). Therefore, the success of this combination therapy most likely resulted from TPCs conversion to differentiated cells via PI3K/AKT1/SOX2 axis inhibition.
Discussion
Along with cancer progression, the differentiated phenotypes are gradually lost, and stem-like features are subsequently acquired by TPCs, resulting in metastasis and resistance to available therapies (1, 2, [46] [47] [48] The data are presented as mean ± SD; n=3. **P<0.01, ***P<0.001, and ****P<0.0001. RCHO-resistant and original cells induced 100% tumor incidence (Table 1) .
Tumor growth rate (E) and paired tumor weight (F) at end-point of experiment.
The data are presented as mean ± SEM; n=5. *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001. 
